Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease

Abstract

Abstract. Chronic obstructive pulmonary disease (COPD) is a severe lung disease characterized by progressive airflow limitation. Salmeterol and formoterol are two commonly used drugs in COPD therapy, which act as β2-receptor agonists. In the current study, a mouse model of COPD induced by airway lipopolysaccharide inhalation was established. The therapeutic efficacy of salmeterol and formoterol co-treatment was investigated in this model over a 56-day-long observation period. It was also identified that functional residual capacity and inspiratory resistance were significantly improved after salmeterol and/or formoterol treatment compared with the control group (all P<0.01). Furthermore, histological staining of lung tissue samples indicated that inflammation, thickening of the smooth muscle, goblet cell hyperplasia and pulmonary small vessel obstruction were reduced in the mice treated with salmeterol and/or formoterol, suggesting that salmeterol and formoterol were beneficial for ongoing airway and blood vessel remodeling in mice with COPD. The most common treatment-associated adverse events were hypertension and proteinuria. In conclusion, combined salmeterol and formoterol treatment was more effective compared with either single agent, suggesting that salmeterol and formoterol combined treatment has therapeutic value for the clinical treatment of patients with COPD.

Prototype Star Fruit-Honey Product and Effectiveness on Antixidants, Inflammation and Walking Distance in Participants with Stable Chronic Obstructive Pulmonary Disease (COPD)

“…10 For instance, previous reports proved that overexpression of tumor necrotic factor-alpha (TNF-∝) in the lung induced the release of superoxide radicals from the macrophage or neutrophils, 11 and a dominantly high level was found in the blood of COPD patients. 12 Medical treatment can be performed clinically in most COPD patients, with various pharmacological agents such as bronchodilators, which act as β 2 -agonists 13 and anticholinergics, 14,15 and anti-inflammatory agents such as prednisolone 16 or a combination of bronchodilator and anti-inflammatory agents like fluticasone 17 and salmeterol (Advair), 18 as well as antibiotics, for example, amoxicillin, tetracycline or azithromycin. 19 However, the non-pharmacological treatments comprise smoking cessation, 20 education, 21 oxygen supplement 22 and pulmonary rehabilitation.…”

miRNA‑101‑3p.1 as an independent diagnostic biomarker aggravates chronic obstructive pulmonary disease via activation of the EGFR/PI3K/AKT signaling pathway

“…chronic obstructive pulmonary disease (coPd) is a chronic disease characterized by persistent airflow restriction and is associated with an abnormal chronic inflammatory response of airways and lung tissues to harmful gases or particles (1,2). Typical clinical manifestations of coPd are chronic cough, sputum, shortness of breath or dyspnea, and wheezing and chest tightness; however, some coPd patients lack clinical manifestations of chronic cough, sputum, or other clinical symptoms before airflow restriction (3,4). Notably, COPD is difficult to precisely diagnose, and it is estimated that only 60-85% of coPd patients are diagnosed in the early to intermediate stages of disease progression (5).…”